I.M. Sechenov First Moscow State Medical University, 2021: Russian trial of methylene blue combined with photodynamic therapy in SARS-CoV-2 patients at Sechenov University, 60 participants, completed, no results posted.
Since methylene blue can work as a photosensitizer, photodynamic therapy as an antiviral treatment has great potential in the treatment of COVID-19.
Registry record field
I.M. Sechenov First Moscow State Medical University, 2021: Russian trial of methylene blue combined with photodynamic therapy in SARS-CoV-2 patients at Sechenov University, 60 participants, completed, no results posted. Registry record field from the API v2 record, hence MEDIUM. Status COMPLETED, actual enrolment 60. Light parameters and MB concentration are not stated in the brief summary. Sponsor: I.M. Sechenov First Moscow State Medical University. 'Registered, no results'. Study type: other.
